Company: ARWR
Filing Date: 2025-05-12
Form Type: 10-Q
Source: 0001628280-25-024666
Chunk: 116

Company: ARROWHEAD PHARMACEUTICALS, INC.
Filing Date: 2025-05-12
Form: 10-Q
Item: Part I, Item 8
Chunk 116
---
 adopted or terminated trading plans intended to satisfy Rule 10b5-1(c), except as set forth in the following table:NameTitleAdoption or Termination DatePlan Start DatePlan End DateSharesVesting andSubject toSell-To-Cover (1)OtherSharesBeing Sold(Subject toCertainConditions)Ken MyszkowskiChief Financial Officer Terminated on 1/6/20256/11/20242/28/2025n/a115,000Ken MyszkowskiChief Financial Officer1/7/20254/10/202512/31/2025n/a170,599James HamiltonChief Medical Officer, Head of R&D2/24/20255/28/202511/30/2026n/a60,000Christopher AnzaloneChief Executive OfficerTerminated on 3/12/202512/4/202412/31/20262,082,892n/a

(1) This column indicates the total number of shares vesting in connection with equity awards, not the number of shares to be sold. The actual number of shares to be sold will be a smaller number based on whatever is required to satisfy payment of applicable withholding taxes under sell-to-cover arrangements. 

32

ITEM 6.    EXHIBITS

ExhibitNumberDocument Description3.1Amended and Restated Certificate of Incorporation (incorporated by reference from Exhibit 3.3 of the Company’s Form 8-K filed on April 6, 2016)3.2Certificate of Amendment to the Amended and Restated Certificate of Incorporation of Arrowhead Pharmaceuticals, Inc. (incorporated by reference from Exhibit 3.2 of the Company’s Form 10-Q filed on May 2, 2023)3.3Second Amended and Restated Bylaws of Arrowhead Pharmaceuticals, Inc., as amended January 24, 2023(incorporated by reference from Exhibit 3.3 of the Company’s Form 10-Q filed on May 2, 2023)10.1*Severance and Change of Control Agreement by and between Company and Christopher Anzalone, dated May 9, 202510.2*Severance and Change of Control Agreement by and between Company and Daniel Apel, dated May 8, 202510.3*Severance and Change of Control Agreement by and between Company and Patrick O'Brien, dated May 9, 202510.4*Se